The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
CONCLUSION: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.PMID:34629286 | DOI:10.1016/j.clml.2021.09.010
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Seval Akpinar Mehmet Hilmi Dogu Serhat Celik Omer Ekinci Ipek Yonal Hindilerden Mehmet Sinan Dal Eren Arslan Davulcu Atakan Tekinalp Fehmi Hindilerden Busra Gokce Ozcan Tuba Hacibekiroglu Mehmet Ali Erkurt Metin Bagci Sinem Namdaroglu Gulten Korkmaz Oktay Source Type: research
More News: Atrial Fibrillation | Bleeding | Cancer & Oncology | Chemotherapy | Lymphoma | Myeloma | Pneumonia | Study | Thrombocytopenia